Opendata, web and dolomites

THERAPROBES SIGNED

Biodegradable fluorescent nanoprobes for early detection of (pre)malignant lesions of the gastrointestinal tract

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 THERAPROBES project word cloud

Explore the words cloud of the THERAPROBES project. It provides you a very rough idea of what is the project "THERAPROBES" about.

quality    successful    gastrointestinal    specificity    life    agents    lesions    tremendous    recur    light    gitract    visualization    scales    sites    curative    improves    asymptomatic    treatment    detected    negatively    appearance    operator    disease    intervention    amenable    sensitivity    fsn    rates    systemic    biodegradable    delineation    sensitive    regular    solely    near    critical    inter    variability    permeability    outcomes    chance    silica    inherent    tract    risk    fsns    augmented    symptomatic    miss    patients    diagnostic    accuracy    subtle    malignant    decrease    33    contrast    resection    80    true    aggressive    applicable    marker    patient    treatments    lack    nanoprobes    misses    white    diagnosis    biopsy    accurately    detect    ablation    diagnosing    gi    time    physician    progress    tumor    endoscopic    rate    impacting    paradigm    50    lesion    accurate    survival    clinical    minus    clinically    requiring    unmet    random    size    routine    therapeutic    reliably    sampling    25    errors    directing    vascular    surveillance    strategy    imaging    progression    ubiquitously    detection    compromises    accumulate    poor    active    optical    fluorescent    endoscopy    site   

Project "THERAPROBES" data sheet

The following table provides information about the project.

Coordinator
PERCUROS BV 

Organization address
address: PLESMANLAAN 1
city: LEIDEN
postcode: 2333 BZ
website: www.percuros.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 187˙572 €
 EC max contribution 187˙572 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PERCUROS BV NL (LEIDEN) coordinator 187˙572.00

Map

 Project objective

Accurate diagnosis of (pre)malignant gastrointestinal (GI)-tract lesions is critical for patient survival. Early detection of asymptomatic disease of the GItract improves the chance of curative intervention by 50−80% as compared to poor five-year survival rates for symptomatic advanced malignant disease. Regular endoscopic surveillance in high-risk patients misses 25% of (pre)malignant lesions – the most clinically relevant marker for malignant progression. This clinically significant miss rate is due to the subtle appearance of such lesions under white-light endoscopy and sampling errors inherent to a random-biopsy surveillance paradigm, which increases inter-operator variability and compromises diagnostic accuracy. Even when malignant disease is detected, lack of sensitive contrast agents compromises delineation of the true extent of the lesion. These factors decrease the physician’s ability to achieve successful therapeutic intervention through resection or ablation. About 33% of GI-tract lesions progress or recur at or near the therapeutic site, commonly requiring aggressive yet often non-curative, systemic treatments negatively impacting the patients’ quality of life. There is an unmet clinical need for endoscopic optical imaging approaches that reliably detect those lesions with high sensitivity and specificity. To develop a clinically viable strategy, I propose to use biodegradable, fluorescent silica nanoprobes (FSN) that provide real-time visualization of the lesions over a range of scales during routine endoscopy. Since FSNs accumulate at the tumor sites solely due to their size and increased vascular permeability, no active targeting is needed, making these imaging agents ubiquitously applicable. Endoscopy augmented with FSNs has tremendous potential for better outcomes particularly in high-risk patients by accurately diagnosing and directing treatment specifically to early lesions at a time when patients are amenable to curative therapeutic intervention.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERAPROBES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERAPROBES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

MultiSeaSpace (2019)

Developing a unified spatial modelling strategy that accounts for interactions between species at different marine trophic levels, and different types of survey data.

Read More  

TxnEvoClim (2019)

Climate adaptation in Arabidopsis thaliana through evolution of transcription regulation

Read More  

ACES (2019)

Antarctic Cyclones: Expression in Sea Ice

Read More